Combined Abrocitinib and Acitretin Therapy for Darier's Disease: A Case Report
Hui Ye,Weifeng Chen,Wenyan Liu,Junhui Zhu,Jingyao Liang,Xibao Zhang
DOI: https://doi.org/10.2147/ccid.s485694
2024-12-06
Clinical Cosmetic and Investigational Dermatology
Abstract:Hui Ye, 1, 2, &ast Weifeng Chen, 1, 2, &ast Wenyan Liu, 1, 2 Junhui Zhu, 1, 2 Jingyao Liang, 1, 2 Xibao Zhang 1, 2 1 Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People's Republic of China; 2 Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, 510095, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jingyao Liang; Xibao Zhang, Guangzhou Dermatology Hospital, No. 56 hengfu Road, Guangzhou, 510095, People's Republic of China, Email ; Darier's disease (DD) is a rare chronic keratinizing skin disease characterized by dyskeratosis of epidermal cells. We report a case of DD with a medical history spanning over 20 years and recurring symptoms. Pathologically confirmed DD was treated with a combination of abrocitinib and acitretin, resulting in rapid symptom resolution within 2 weeks. No recurrence was noted in an 11-week follow-up. The mechanism may involve acitretin's inhibition of proliferation and anti-inflammation, while abrocitinib acts on IL-6 implicated in DD pathogenesis, exerting an immunomodulatory and anti-inflammatory effect, leading to rapid symptom relief. The combination of abrocitinib and acitretin is an effective therapy for DD, offering a promising new option for refractory patients. Keywords: keratosis follicularis, Darier's disease, abrocitinib, acitretin Darier's disease (DD), also referred to as Keratosis Follicularis, is an autosomal dominant genetic disorder with a prevalence rate ranging from 1 in 300,000 to 100,000. It exhibits no significant sex difference. 1,2 DD typically manifests in childhood, persisting through puberty, presenting with various clinical features, including scales, plaques, scabs, palmoplantar keratoma, and fragile fingernails and toenails. 2 DD may be accompanied by non-cutaneous symptoms, including mental aspects such as mental retardation, epilepsy, or bipolar disorder. 2 Various treatment modalities are available for DD. To date, several conventional treatments have been reported, but long-term remission of the disease is difficult to achieve. Topical corticosteroids have poor therapeutic effects and are prone to recurrence after discontinuation. 3 Systemic Acitretin is among the treatment options, exhibiting a certain therapeutic effect, albeit with individual variations. 1 Ablative therapies (dermabrasion, CO2 laser, Er: YAG laser) are effective but limited by the size of the areas that can be treated. 4 Intermittent courses of therapy or long-term maintenance may be required in the management of DD. Abrocitinib, a highly selective JAK1 inhibitor, demonstrates immunomodulatory and anti-inflammatory effects. A 32-year-old female presented with follicular papules on the head, neck, upper limbs, and trunk, along with oil scabs persisting for 20 years. Two decades ago, the patient initiated the development of craniofacial papules and oil scabs, progressively extending to the trunk and upper limbs. This condition, marked by itching, underwent repetitive symptomatic treatment involving both traditional Chinese and Western medicine. Despite recurrent symptoms, there was no evident growth and development, no mental abnormalities, and no comparable family medical history. Physical examination revealed irregular follicular papules conglomerating on the scalp, face, neck, and trunk, along with surface oil scabs. Brown papules and nodules were dispersed on the back and vulva of both hands, accompanied by irregular white longitudinal lines on the fingernails and triangular defects on the free edge of the nails (Figure 1, a1–e1). To rule out secondary causes of DD, a series of examinations were conducted, including complete blood count, liver and kidney function tests, fasting sugar levels, thyroid function tests, hormone level examination, tumor marker examination and anti nuclear antibody test. All the reports were found within normal limits. Microscopic examination revealed complete pathology, including hyperkeratosis, dyskeratosis, corps ronds and grains, acantholysis, and superficial and middle dermis lymphocyte infiltration (Figure 2). Figure 1 A 32-year-old female presented with before abrocitinib and Acitretin treatment ( a1 – e1 ); keratinized papules and oil scabs on the face, neck, and trunk disappeared, and local erythema and brown papules on the back of both hands flattened 2 weeks after treatment ( a2 – e2 ); the erythema area was reduced compared to baseline 6 weeks after treatment ( a3 – d3 ); a s -Abstract Truncated-
dermatology